D. Scott Neal’s Pacira BioSciences PCRX Stock Holding History

D. Scott Neal’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200	Closed	-$9K	–	175
2017 Q4	$9K	Hold	200	–	–	0.01%	130
2017 Q3	$8K	Hold	200	–	–	﹤0.01%	140
2017 Q2	$10K	Hold	200	–	–	0.01%	142
2017 Q1	$9K	Hold	200	–	–	0.01%	121
2016 Q4	$6K	Hold	200	–	–	﹤0.01%	129
2016 Q3	$7K	Hold	200	–	–	0.01%	121
2016 Q2	$7K	Hold	200	–	–	0.01%	121
2016 Q1	$11K	Sell	200 -200	-50%	-$11.7K	0.01%	99
2015 Q4	$31K	Buy	+400	New	+$22.6K	0.02%	71

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

D. Scott Neal's PCRX Position: Q1 2018 in Review

D. Scott Neal sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 200 shares — an estimated $9K sold.

D. Scott Neal first reported a position in PCRX in Q4 2015 and held it in 9 quarters. The position peaked at $31K in Q4 2015. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

D. Scott Neal reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
D. Scott Neal sold 200 Pacira BioSciences shares in Q1 2018, an estimated $9K.
D. Scott Neal first reported a position in Pacira BioSciences in Q4 2015 and held it in 9 quarters.
D. Scott Neal's Pacira BioSciences position peaked at $31K in Q4 2015.
168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on D. Scott Neal's 13F filing for Q1 2018, filed 19 Apr 2018.